Maria Diab

GI oncologist @HenryFordHealth with a focus on #pancreaticcancer; optimistic realist; wife, mother, fellow human. Opinions are my own.

[PanCAN @PanCAN]

Today, the U.S. Food and Drug Administration (FDA) announced that it has issued a “safe to proceed” letter to @RevMedicines, allowing the company to initiate an expanded access treatment protocol (EAP) for daraxonrasib for patients with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC). 💊

Expanded access is a potential pathway for patients with serious or life-threatening conditions to gain access to investigational medicines outside of a clinical trial when they are unable to participate in a clinical trial and all other appropriate treatment options have been exhausted.

In response to the FDA’s letter, Revolution Medicines said that this “represents a critical step in the process of opening an EAP” and that they are “moving as quickly as possible to ensure safe and equitable access to daraxonrasib for eligible patients in the United States,” according to a statement from the company.

Read Revolution Medicines’ Expanded Access Policy, including how to submit a request through a licensed treating physician and how daraxonrasib is extending survival for #pancreaticcancer patients at 🔗 https://t.co/hzw7yln7wo.

[Maria Diab @MariaDiab101]

@IbrahimSahinMD1 Pleasure to have you!

[Binaytara @binaytara]

Final Call! The CME/CE-accredited Detroit 2026 Hematology and Oncology Practice Symposium is just around the corner! Led by Drs. @FawziAbuRous and @MariaDiab101 , this interactive symposium will deliver practice-changing insights across lung, GI, GU, breast, and hematologic cancers—along with a keynote on the evolving role of antibody-drug conjugates. Register NOW: https://t.co/hEa94FGekh #CMEConference #Oncology #Hematology #CancerCare #Binaytara #HemOnc #MedTwiiter #MedX

[SWOG Cancer Research Network @SWOG]

Just activated!
#NCTN S2433 trial is enrolling patients with locally advanced or metastatic #pancreatic ductal
adenocarcinoma without KRAS or BRAF V600E mutations. Randomized to physician’s choice
SOC w/wo panitumumab.
PI: Rachael A. Safyan, MD @fredhutch
https://t.co/TeBHJ8kgdL

[Maria Diab @MariaDiab101]

@Dr_M_Tejani 12 months.

[Binaytara @binaytara]

Last chance to register! Join @FawziAbuRous, @MariaDiab101, and other leading #oncology experts from @HenryFordHealth, @karmanoscancer, @UMRogelCancer, @umichmedicine @UMichRadOnc, @IHACares and @CorewellHealth at the CME/MOC-accredited #DetroitHemOnc25 in #Detroit! Register NOW: https://t.co/outxQLWRRa
#HemOnc #MedEd #MedX #MedTwitter

[Maria Diab @MariaDiab101]

@RAFrancescone @farali2009 @DebVendramini @arianamusa @myree_g Congratulations!!!

[Maria Diab @MariaDiab101]

@FawziAbuRous @HenryFordHealth @LungCancerRx @HFHemOncFellows @IMG_Oncologists @HemOncFellows Congratulations!!

[Maria Diab @MariaDiab101]

@WinshipAtEmory Go Sujata!

[Shruti Patel, MD @ShrutiPatelMD]

Came across @ShaalanBeg & @cancerassassin1 having a heated debate at #ASCO24

An Annual Meeting classic 🫡

[Maria Diab @MariaDiab101]

@AnwaarSaeed3 @SWOG @NCICTEP_ClinRes @UPMCHillmanCC @paphilip @CathyEngMD @danduda9 @RajivAgarwalMD Congrats!!

[Anirban Maitra @Aiims1742]

Preprint from @HenryFordHealth #PancreaticCancer research team (@HCCvPDAC @Daniel_Salas671 @NinaSteele17) + @DelgiornoKathy @SearsRosie
Metaplastic tuft cells transdifferentiate to neural-like progenitor cells in the progression of #PancreaticCancer
https://t.co/2jO4rsqKLz

Mostly curious how long this took(😱):
Ptf1aFlpO/+; FSF-KRASG12D/+; Trp53Frt-Exons 2 to 5-Frt/+; Pou2f3CreERT/+; ROSA26LSL-TdTomato/+, a.k.a. “KPF-P2f3T” mice.
https://t.co/2jO4rsqKLz

[PanCAN @PanCAN]

The 5-year survival rate for #pancreaticcancer has increased to 13%, according to the American Cancer Society’s Cancer Facts & Figures 2024 Report, released today. 💜

This statistic has increased three years in a row — a promising trend that points to continued progress for pancreatic cancer patients. There is more hope than ever before, but there is still more work to be done.

We remain committed to our long-standing research priorities: To find an early detection strategy and accelerate treatments for patients with pancreatic cancer. We’re on the right path to achieve our bold goal of reaching a five-year survival rate of 20% by 2030. Together, we can make it happen. 💪

Learn more about what this means for patients at: https://t.co/F7qmwLBxZo.

[ASCO @ASCO]

A recording of Dr. @KimmieNgMD's #GI24 keynote lecture is now available, "The Growing Problem of Early-Onset Gastrointestinal Cancers."

Watch here ➡️ https://t.co/oEpW2D1UQu #gicsm #OncTwitter

[ASCO @ASCO]

With an armamentarium of drugs with different MOAs, how should we sequence therapies for advanced #HepatocellularCarcinoma? @MariaDiab101 & Dr. Philip A. Philip discuss: https://t.co/lMznIyRkZk #gicsm #ASCODailyNews

[Maria Diab @MariaDiab101]

@AnwaarSaeed3 @CellPressNews @CellRepMed @UPMCHillmanCC @rprobinpark @OncoAlert @PittDeptofMed @UPMCnews @ExelixisInc @AstraZeneca @FightCRC @CrcTrialsChat @colontown Congratulations!

[Mark Lewis, MD, FASCO @marklewismd]

Every New Year's Eve I take the grim but necessary inventory of the patients I've lost

As a GI oncologist I've watched more than 60 -- more than 1 a week -- dear people succumb to their illness in 2022

They will not be forgotten

We must do better

And there is real hope we can

[Maria Diab @MariaDiab101]

@AnwaarSaeed3 @WinshipAtEmory @KUcancercenter Was so nice connecting with you again my friend. All the best!

[Maria Diab @MariaDiab101]

Very useful pearls regarding the fellowship match.

[Bassel Nazha, MD, MPH @BasselNazha]

I’ve spent time thinking about the fellowship match & I’ve interviewed applicants since joining faculty

Here's a 🧵about the fellowship match
@WinshipAtEmory #MedTwitter
1/